180 related articles for article (PubMed ID: 38254769)
1. PRAME Is an Effective Tool for the Diagnosis of Nevus-Associated Cutaneous Melanoma.
Ronchi A; Cazzato G; Ingravallo G; D'Abbronzo G; Argenziano G; Moscarella E; Brancaccio G; Franco R
Cancers (Basel); 2024 Jan; 16(2):. PubMed ID: 38254769
[TBL] [Abstract][Full Text] [Related]
2. [Application of immunohistochemical staining of PRAME in differential diagnosis between melanoma and melanocytic nevus].
Du J; Yu WJ; Guo RP; Su J
Zhonghua Bing Li Xue Za Zhi; 2022 Jul; 51(7):621-626. PubMed ID: 35785832
[No Abstract] [Full Text] [Related]
3. Potential diagnostic utility of PRAME and p16 immunohistochemistry in melanocytic nevi and malignant melanoma.
Bahmad HF; Oh KS; Alexis J
J Cutan Pathol; 2023 Aug; 50(8):763-772. PubMed ID: 37114299
[TBL] [Abstract][Full Text] [Related]
4. The utility of PRAME staining in identifying malignant transformation of melanocytic nevi.
Lohman ME; Steen AJ; Grekin RC; North JP
J Cutan Pathol; 2021 Jul; 48(7):856-862. PubMed ID: 33433032
[TBL] [Abstract][Full Text] [Related]
5. PRAME expression by immunohistochemistry and reverse transcription quantitative PCR in conjunctival melanocytic lesions-a comprehensive clinicopathologic study of 202 cases and correlation of cytogenetics with PRAME expression in challenging conjunctival melanocytic lesions.
Mudhar HS; Milman T; Stevenson S; Watson M; Kim J; Magan T; Salvi SM; Harley U; Lally SE; Shields CL
Hum Pathol; 2023 Apr; 134():1-18. PubMed ID: 36804828
[TBL] [Abstract][Full Text] [Related]
6. PRAME Expression in Challenging Dermal Melanocytic Neoplasms and Soft Tissue Tumors With Melanocytic Differentiation.
Kline N; Menge TD; Hrycaj SM; Andea AA; Patel RM; Harms PW; Chan MP; Bresler SC
Am J Dermatopathol; 2022 Jun; 44(6):404-410. PubMed ID: 34991102
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic utility of PRAME expression by immunohistochemistry in subungual and non-subungual acral melanocytic lesions.
Rothrock AT; Torres-Cabala CA; Milton DR; Cho WC; Nagarajan P; Vanderbeck K; Curry JL; Ivan D; Prieto VG; Aung PP
J Cutan Pathol; 2022 Oct; 49(10):859-867. PubMed ID: 35794643
[TBL] [Abstract][Full Text] [Related]
8. PRAME Expression in Melanocytic Tumors.
Lezcano C; Jungbluth AA; Nehal KS; Hollmann TJ; Busam KJ
Am J Surg Pathol; 2018 Nov; 42(11):1456-1465. PubMed ID: 30045064
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemistry for PRAME in Dermatopathology.
Lezcano C; Jungbluth AA; Busam KJ
Am J Dermatopathol; 2023 Nov; 45(11):733-747. PubMed ID: 37856737
[TBL] [Abstract][Full Text] [Related]
10. PRAME expression in cutaneous melanoma does not correlate with disease-specific survival.
Parra O; Ma W; Li Z; Coffing BN; Linos K; LeBlanc RE; Momtahen S; Sriharan A; Cloutier JM; Wells WA; Yan S
J Cutan Pathol; 2023 Oct; 50(10):903-912. PubMed ID: 37430414
[TBL] [Abstract][Full Text] [Related]
11. PRAME immunohistochemistry of spitzoid neoplasms.
Koh SS; Lau SK; Scapa JV; Cassarino DS
J Cutan Pathol; 2022 Aug; 49(8):709-716. PubMed ID: 35488519
[TBL] [Abstract][Full Text] [Related]
12. Refining the application of PRAME-a useful marker in high CSD and acral melanoma subtypes.
Wakefield C; O'Keefe L; Heffron CCBB
Virchows Arch; 2023 Dec; 483(6):847-854. PubMed ID: 37723345
[TBL] [Abstract][Full Text] [Related]
13. PRAME is a useful marker for the differential diagnosis of melanocytic tumours and histological mimics.
Chen YP; Zhang WW; Qiu YT; Ke LF; Chen H; Chen G
Histopathology; 2023 Jan; 82(2):285-295. PubMed ID: 36200756
[TBL] [Abstract][Full Text] [Related]
14. FLI-1/Melan-A dual stain is an alternative to PRAME in differentiating metastatic melanoma from nodal nevus: A monocentric retrospective study.
Zengin HB; Yildiz B; Pukhalskaya T; Smoller BR
J Cutan Pathol; 2023 Mar; 50(3):247-258. PubMed ID: 36454046
[TBL] [Abstract][Full Text] [Related]
15. Comparative Analysis of PRAME Expression in 127 Acral and Nail Melanocytic Lesions.
Santandrea G; Valli R; Zanetti E; Ragazzi M; Pampena R; Longo C; Lai M; Piana S; Cesinaro AM
Am J Surg Pathol; 2022 May; 46(5):579-590. PubMed ID: 35275883
[TBL] [Abstract][Full Text] [Related]
16. Preferentially Expressed Antigen in Melanoma Immunostaining in a Series of Melanocytic Neoplasms.
Googe PB; Flanigan KL; Miedema JR
Am J Dermatopathol; 2021 Nov; 43(11):794-800. PubMed ID: 33989214
[TBL] [Abstract][Full Text] [Related]
17. PRAME immunohistochemistry is useful in the evaluation of conjunctival melanomas, nevi, and primary acquired melanosis.
LeBlanc RE; Miller DM; Zegans ME
J Cutan Pathol; 2021 Dec; 48(12):1442-1448. PubMed ID: 34089198
[TBL] [Abstract][Full Text] [Related]
18. A Comparison of Preferentially Expressed Antigen in Melanoma Immunohistochemistry and Diagnostic Gene Expression-Profiling Assay in Challenging Melanocytic Proliferations.
Casillas AC; Muhlbauer A; Barragan VA; Jefferson I; Speiser JJ
Am J Dermatopathol; 2024 Mar; 46(3):137-146. PubMed ID: 38354382
[TBL] [Abstract][Full Text] [Related]
19. Comparison of Immunohistochemistry for PRAME With Cytogenetic Test Results in the Evaluation of Challenging Melanocytic Tumors.
Lezcano C; Jungbluth AA; Busam KJ
Am J Surg Pathol; 2020 Jul; 44(7):893-900. PubMed ID: 32317605
[TBL] [Abstract][Full Text] [Related]
20. Immunohistochemistry for PRAME in the Distinction of Nodal Nevi From Metastatic Melanoma.
Lezcano C; Pulitzer M; Moy AP; Hollmann TJ; Jungbluth AA; Busam KJ
Am J Surg Pathol; 2020 Apr; 44(4):503-508. PubMed ID: 31633488
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
